Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension
نویسندگان
چکیده
منابع مشابه
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
BACKGROUND Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not pre...
متن کاملAmbrisentan therapy for pulmonary arterial hypertension.
OBJECTIVES The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH). BACKGROUND Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options. Endothelin is a vasoconstrictor and smooth muscle cell ...
متن کاملTadalafil therapy for pulmonary arterial hypertension.
BACKGROUND Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. METHODS AND RESULTS In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated),...
متن کاملright ventricular strain and strain rate in patients with systemic sclerosis without pulmonary hypertension
conclusions this study indicated that the rv systolic strain and strain rate can be used to detect early rv systolic dysfunction in ssc patients without pulmonary hypertension. these parameters may be useful for the provision of a more adequate management of ssc patients. results in the ssc patients, the rv strain (- 19 ± 10 vs. - 25 ± 4 %; p = 0.004) and the systolic strain rate (- 1.3 ± 0.5 v...
متن کاملRight ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension.
BACKGROUND Systemic sclerosis–associated pulmonary artery hypertension (SScPAH) has a worse prognosis compared with idiopathic pulmonary arterial hypertension (IPAH), with a median survival of 3 years after diagnosis often caused by right ventricular (RV) failure. We tested whether SScPAH or systemic sclerosis–related pulmonary hypertension with interstitial lung disease imposes a greater pulmo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Respiratory and Critical Care Medicine
سال: 2018
ISSN: 1073-449X,1535-4970
DOI: 10.1164/rccm.201704-0789le